Continuing mumps outbreak in Keralam leads to renewed demand for MMR vaccine

Mumps is a contagious viral infection that can cause swelling of the salivary glands and other complications. It spreads mainly through saliva and respiratory droplets when infected children cough, sneeze, talk closely or share items. The article focuses on its continuing spread among children and the protection vaccines can provide.

In Keralam, outbreaks have affected schools and hostels, forcing closures in Alappuzha, Thrissur and Kottayam. Such settings bring children into close contact, allowing the virus to move quickly, especially when children lack mumps vaccination. The article reports that the UIP provides measles-rubella vaccine, not protection against mumps.

The continuing outbreak shows why transmission matters even when mortality is low. India recorded 74,907 cases in Keralam during 2024 and 26,462 in 2025. Better surveillance, vaccination and documentation of complications could reduce spread and reveal the disease’s full impact.

The outbreak in Keralam has grown far beyond its usual scale. Mumps infections began surging in November 2023, after an annual average of more than 2,000 cases. The figures show a sustained outbreak rather than a brief increase, with cases continuing into 2026.

Keralam reported 74,907 cases in 2024 and 26,462 in 2025. A further 6,606 cases had been reported in 2026 by the article’s publication date. The 2024 total was roughly 37 times the usual annual average of 2,000 cases, while the 2025 figure was about 13 times higher.

The scale has had practical consequences. Outbreaks forced schools and hostels to close for weeks in Alappuzha, Thrissur and Kottayam. The continuing numbers have strengthened demands to add MMR vaccination to the Universal Immunisation Programme and improve surveillance of complications and disability.

MR and MMR are combined vaccines with different coverage. The measles-rubella vaccine provided through India’s Universal Immunisation Programme protects against measles and rubella. It does not protect against mumps. The MMR vaccine adds mumps protection, covering all three infections.

This difference matters because mumps outbreaks continue in Keralam and other States. The UIP provides two MR doses, while MMR has been available to children through India’s private sector since the 1980s. The Indian Academy of Paediatrics has long recommended MMR in place of MR.

The debate concerns public protection, cost and disease burden. The Centre said adding mumps would more than double the vaccine cost compared with MR, without proportionate additional health benefits. Supporters argue that mumps complications and long-term outcomes are poorly documented, so the comparison should include disability, health-care costs and school absenteeism.

Mumps outbreaks can cause more than a short illness. The article describes complications including acute pancreatitis, encephalitis and aseptic meningitis. It also says the virus can affect reproductive glands in both sexes, with consequences that may appear only later.

One especially serious outcome is sensorineural hearing loss. K.K. Purushothaman calls mumps a leading cause of acquired sensorineural hearing loss in children. Nerve damage can produce permanent, irreversible deafness. This makes low mortality an incomplete measure of the disease’s public-health impact.

Outbreaks also disrupt daily life and education. Schools and hostels in Alappuzha, Thrissur and Kottayam closed for weeks. Paediatricians argue that complications, disabilities, health-care costs and school absenteeism should be systematically documented. Those effects could change how India evaluates the value of adding MMR to the UIP.

India has given mumps lower immunisation priority because the disease has relatively low mortality. The Centre’s response says vaccine decisions consider disease prevalence, incidence, mortality, efficacy and cost-effectiveness. NTAGI has also considered mumps-associated disability not a significant public-health concern.

Cost is another reason. The Centre said adding the mumps component would more than double the cost compared with the MR vaccine, without proportionate additional health benefits. Meanwhile, the UIP provides two MR doses, leaving mumps outside the publicly funded combination.

Paediatricians challenge this approach because mumps morbidity and long-term complications are poorly documented. They point to deafness, neurological complications, reproductive effects, school closures and health-care costs. They argue that systematic surveillance and a full economic evaluation could produce a different assessment of mumps’ importance and the value of MMR.

The genetic difference is a warning for investigation, not proof of vaccine failure. A Keralam study identified genotype C among viruses circulating during 2024–25. The mumps vaccine uses genotype N, also called the L-Zagreb strain. The two genotypes are genetically different.

The researchers therefore called for continued molecular surveillance. Tracking viral evolution can help scientists understand circulating strains and evaluate whether the current vaccination strategy remains appropriate. However, genetic distance alone does not show that vaccine-induced protection fails against the circulating virus.

The study also reported seroepidemiological evidence and outbreak patterns indicating a considerable mumps burden. That finding supports concern about prevention gaps, but it does not settle vaccine effectiveness. More evidence would be needed, including systematic surveillance and evaluation of vaccination outcomes. The article says the study adds another dimension to the debate, rather than providing a final answer.

Public-health experts use cost-effectiveness analysis to compare vaccine costs with health benefits. The question is not simply whether one vaccine costs more. It is whether the extra spending prevents enough illness, disability and wider disruption to justify that cost.

For MMR, the comparison should include complications such as encephalitis, meningitis, pancreatitis, reproductive-gland effects and permanent hearing loss. It should also count health-care expenses, long-term disability and school absenteeism. The article says these effects are poorly documented, making a confident assessment difficult.

Paediatricians therefore call for transparent vaccine-price comparisons, systematic complication surveillance and an economic evaluation using current evidence. The Centre says adding mumps would more than double the cost compared with MR without proportionate benefits. A fuller calculation could test that conclusion against the costs of outbreaks, treatment, disability and missed education.